血液静止剂的凝血潜力与低度的埃米齐祖马布同时使用 在严重的血友病下 状态 A 状态
Yuki Kawasaki1, Yuto Nakajima1, Keiji Nogami1
1Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan.
概括
绕过剂 (BPA) 在低剂量埃米齐祖马布治疗的血友病A患者中显示出不同的凝血潜力. 建议对BPA剂量进行调整,以在这些人中获得最佳治疗结果.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
- 血栓形成的研究研究
背景情况:
- 艾米齐祖马布用于血友病A (HA),典型的血度为30-50μg/mL.
- 一些患者通过较低的埃米齐祖马布剂量获得有效治疗.
- 关于在低度埃米齐祖马布下绕道剂 (BPA) 的凝血潜力存在有限的数据.
研究的目的:
- 为了评估血友病A (HA) 患者血中BPAs的凝血潜力,患者血中埃米齐祖马布度较低.
- 了解BPA如何与低剂量埃米齐祖马布在HA治疗中的相互作用.
主要方法:
- 用血栓生成试验来评估FVIII或BPAs在FVIII缺乏血中与埃米齐祖马布 (2.5-10μg/mL) 的影响.
- 测试的BPA包括复合FVIIa (rFVIIa),激活型血红素复合物缩物 (aPCC) 和血衍生FVIIa/FX (pd-FVIIa/FX).
- 还在10名接受埃米齐祖马布治疗的HA患者的血中监测了凝血潜力 (装载和维护阶段),并添加了BPAs.
主要成果:
- 艾米齐祖马布与FVIII一起显示出与单独的FVIII相比可以比较的血栓生成.
- 埃米齐祖马布与BPA结合,导致比单独的BPA产生轻微到明显更大的血栓生成.
- 激活型前列红素复合物缩剂 (aPCC) 和血衍生型FVIIa/FX (pd-FVIIa/FX) 在经过治疗的HA血中增加了凝血潜力.
- 复合FVIIa (rFVIIa) 在90μg/kg时没有在加载阶段增强凝血,但在维护阶段改善了凝血;在270μg/kg时,它在加载阶段增强凝血.
结论:
- 绕过剂 (BPA) 的有效性可能会受到埃米齐祖马布度的影响.
- 在接受低剂量艾米齐祖马布的血友病A患者中,BPA的剂量调整可能是必要的.
- 考虑埃米齐祖马布水平和BPA疗效的个性化治疗策略至关重要.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
919
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
919
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Venous Thrombosis III: Interprofessional Care
26
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
26
Disorders of Hemostasis
1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K
Extrinsic and Intrinsic Pathways of Hemostasis
9.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.3K
Introduction to Hemostasis
9.0K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
9.0K


